ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1105

RANK-L Activity: Understanding the Pathogenesis of Erosive Osteoarthritis
Abstract Number: 1551

Rapid Effect of Tofacitinib in Reducing US Joint and Tendon Inflammatory Lesions of RA Patients: Data from a 24 Weeks Longitudinal Study
Abstract Number: 0458

Rapid Implementation of a Multidisciplinary COVID-19 Cytokine Storm Syndrome Task Force
Abstract Number: 1377

Raynaud’s Phenomenon and Systemic Sclerosis in Post-9/11 Deployed Veterans Receiving Care Veterans Health Administration Care
Abstract Number: 1253

Re-evaluation of the Extent of Lymphocytic Infiltration May Improve the Diagnostic Accuracy of Lip Biopsy in Primary Sjögren’s Syndrome (pSS)
Abstract Number: 1219

Reaching Remission by IL-1 Inhibition in Rheumatoid Arthritis Patients with Type 2 Diabetes Improves the Glucose Homeostasis: Long-term Findings from TRACK Study, a Multicentre, Open-label, Randomised, Controlled Trial
Abstract Number: 0651

Readmission Risk and Quality of Care in Patients Presenting to the Emergency Department with Gout Flares
Abstract Number: 1683

Ready or Not? Measuring Readiness for Transition to Adult Care in Adolescents with JIA & jSLE
Abstract Number: 0227

Real Life Severe Infections in Patients with Rheumatoid Arthritis on Treatment with Biological Therapy and JAK Inhibitors
Abstract Number: 1031

Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab
Abstract Number: 0802

Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Effectiveness
Abstract Number: 0803

Real-World DMARD Experience and Outcomes for Rheumatoid Arthritis Patients in Japan: Safety
Abstract Number: 1381

Real-World Mono-, Double and Triple Combination Treatment Patterns with Macitentan in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (PAH-CTD): Evidence from the Combined OPUS/OrPHeUS Dataset
Abstract Number: 0812

Real-World Utilization of Infliximab (IFX) and Its Biosimilars in Patients (Pts) with Rheumatoid Arthritis (RA) Since the First Biosimilar Approval in the US
Abstract Number: 0556

Recent Use, Missed Doses and Discontinuation of Infliximab in New-users: Comparisons of Biosimilar and Originator Exposures

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].